Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| Weiss Ratings | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | 0.00% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -56.00% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.25 | |||
| 52-Week Low Price | $0.11 | |||
| 52-Week Low Price (Date) | Oct 17, 2024 | |||
| 52-Week High Price (Date) | May 06, 2024 | |||
| Valuation | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 53.92M | |||
| Enterprise Value | 53.27M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | -37.47% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 22.45 | |||
| Price/Book (Q) | 1,100.00 | |||
| Enterprise Value/Revenue (TTM) | 18.52 | |||
| Price | $0.11 | |||
| Enterprise Value/EBITDA (TTM) | -2.10 | |||
| Enterprise Value/EBIT | -2.07 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 241.47M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 669 0555 | |||
| Address | 1100 Melville Street Vancouver, BC V6E 4A6 | |||
| Website | ondinebio.com | |||
| Country | Canada | |||
| Year Founded | 1996 | |||
| Profitability | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -893.74% | |||
| Profit Margin | -873.45% | |||
| Management Effectiveness | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -157.91% | |||
| Return on Equity | -- | |||
| Income Statement | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.21M | |||
| Total Revenue (TTM) | 1.21M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 724.10K | |||
| EBITDA (TTM) | -10.64M | |||
| EBIT (TTM) | -10.78M | |||
| Net Income (TTM) | -10.54M | |||
| Net Income Avl. to Common (TTM) | -10.54M | |||
| Total Revenue Growth (Q YOY) | 97.05% | |||
| Earnings Growth (Q YOY) | 3.54% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 22.52% | |||
| Balance Sheet | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 889.90K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 2.35M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 13.90K | |||
| Current Ratio (Q) | 0.804 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 2.94M | |||
| Total Current Liabilities (Q) | 2.93M | |||
| Total Debt (Q) | 256.50K | |||
| Total Liabilities (Q) | 2.93M | |||
| Total Common Equity (Q) | 13.90K | |||
| Cash Flow | OBIMF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -9.60K | |||
| Cash from Financing (TTM) | 6.85M | |||
| Net Change in Cash (TTM) | -2.37M | |||
| Levered Free Cash Flow (TTM) | -4.97M | |||
| Cash from Operations (TTM) | -9.27M | |||
